Fox Run Management L.L.C. Takes $778,000 Position in ANI Pharmaceuticals, Inc. $ANIP

Fox Run Management L.L.C. purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 8,490 shares of the specialty pharmaceutical company’s stock, valued at approximately $778,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Semanteon Capital Management LP purchased a new stake in ANI Pharmaceuticals during the third quarter valued at about $556,000. Mitsubishi UFJ Asset Management UK Ltd. raised its holdings in shares of ANI Pharmaceuticals by 60.0% during the third quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $733,000 after acquiring an additional 3,000 shares during the period. Persistent Asset Partners Ltd purchased a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $660,000. Public Sector Pension Investment Board boosted its stake in ANI Pharmaceuticals by 16.1% in the 3rd quarter. Public Sector Pension Investment Board now owns 67,377 shares of the specialty pharmaceutical company’s stock worth $6,172,000 after purchasing an additional 9,324 shares during the period. Finally, Illinois Municipal Retirement Fund boosted its stake in ANI Pharmaceuticals by 1.7% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after purchasing an additional 145 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Barclays started coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $103.43.

Insider Transactions at ANI Pharmaceuticals

In related news, insider Christopher Mutz sold 5,323 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $78.02, for a total transaction of $415,300.46. Following the transaction, the insider owned 84,840 shares of the company’s stock, valued at approximately $6,619,216.80. This trade represents a 5.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $77.53, for a total transaction of $161,572.52. Following the completion of the sale, the senior vice president owned 50,993 shares of the company’s stock, valued at $3,953,487.29. This trade represents a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 13,459 shares of company stock valued at $1,066,611. 11.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Trading Up 1.1%

NASDAQ ANIP opened at $77.15 on Friday. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals, Inc. has a 1-year low of $54.56 and a 1-year high of $99.50. The firm’s fifty day simple moving average is $80.37 and its 200-day simple moving average is $86.47. The company has a market capitalization of $1.73 billion, a PE ratio of 47.33 and a beta of 0.50.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.